Updated
Reviewed
Apr. 07, 2021

Management of Medication Toxicity or Intolerance

Osteopenia and Osteoporosis

Table 15j. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis
Table 15j. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis
   
   
   
   

 

References

  1. Arpadi SM, Shiau S, Strehlau R, et al. Efavirenz is associated with higher bone mass in South African children with HIV. AIDS. 2016;30(16):2459-2467. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27427876.
  2. Aurpibul L, Cressey TR, Sricharoenchai S, et al. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. Pediatr Infect Dis J. 2015;34(4):392-397. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25760566.
  3. Bachrach LK, Gordon CM, Section on Endocrinology. Bone densitometry in children and adolescents. Pediatrics. 2016;138(4). Available at: https://www.ncbi.nlm.nih.gov/pubmed/27669735.
  4. Baranek B, Wang S, Cheung AM, et al. The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. Antivir Ther. 2020;25(1):21-32. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32077867.
  5. Burt LA, Billington EO, Rose MS, et al. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial. JAMA. 2019;322(8):736-745. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31454046.
  6. Eckard AR, Mora S. Bone health in HIV-infected children and adolescents. Curr Opin HIV AIDS. 2016;11(3):294-300. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26890208.
  7. Eckard AR, O'Riordan MA, Rosebush JC, et al. Effects of vitamin D supplementation on bone mineral density and bone markers in HIV-infected youth. J Acquir Immune Defic Syndr. 2017;76(5):539-546. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28902705.
  8. Gregson CL, Hartley A, Majonga E, et al. Older age at initiation of antiretroviral therapy predicts low bone mineral density in children with perinatally-infected HIV in Zimbabwe. Bone. 2019;125:96-102. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31082498.
  9. Havens PL, Long D, Schuster GU, et al. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone. Antivir Ther. 2018;23(7):623-628. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30260797.
  10. Havens PL, Stephensen CB, Van Loan MD, et al. Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency virus infection being treated with tenofovir disoproxil fumarate: a randomized, placebo-controlled trial. Clin Infect Dis. 2018;66(2):220-228. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29020329.
  11. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21646368.
  12. Jacobson DL, Lindsey JC, Gordon C, et al. Alendronate improves bone mineral density in children and adolescents perinatally infected with human immunodeficiency virus with low bone mineral density for age. Clin Infect Dis. 2020;71(5):1281-1288. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31573608.
  13. Jacobson DL, Yu W, Hazra R, et al. Fractures in children and adolescents living with perinatally acquired HIV. Bone. 2020;139:115515. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32619695.
  14. LaFleur J, Bress AP, Myers J, et al. Tenofovir-associated bone adverse outcomes among a US national historical cohort of HIV-infected veterans: risk modification by concomitant antiretrovirals. Infect Dis Ther. 2018;7(2):293-308. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29492905.
  15. Lima LR, Silva RC, Giuliano Ide C, et al. Bone mass in children and adolescents infected with human immunodeficiency virus. J Pediatr (Rio J). 2013;89(1):91-99. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23544816.
  16. Lindsey JC, Jacobson DL, Spiegel H, et al. Safety and efficacy of 48 and 96 weeks of alendronate in children and adolescents with perinatal HIV infection and low bone mineral density for age. Clin Infect Dis. 2020;ciaa861. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32584996.
  17. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16(1):43-52. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26538525.
  18. Negredo E, Langohr K, Bonjoch A, et al. High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. J Antimicrob Chemother. 2018;73(9):2452-2459. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29860519.
  19. Okonkwo RI, Weidmann AE, Effa EE. Renal and bone adverse effects of a tenofovir-based regimen in the treatment of HIV-infected children: a systematic review. Drug Saf. 2016;39(3):209-218. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26692394.
  20. Overton ET, Chan ES, Brown TT, et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med. 2015;162(12):815-824. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26075752.
  21. Palchetti CZ, Szejnfeld VL, de Menezes Succi RC, et al. Impaired bone mineral accrual in prepubertal HIV-infected children: a cohort study. Braz J Infect Dis. 2015;19(6):623-630. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26477385.
  22. Penner J, Ferrand RA, Richards C, et al. The impact of vitamin D supplementation on musculoskeletal health outcomes in children, adolescents, and young adults living with HIV: a systematic review. PLoS One. 2018;13(11):e0207022. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30439968.
  23. Puthanakit T, Wittawatmongkol O, Poomlek V, et al. Effect of calcium and vitamin D supplementation on bone mineral accrual among HIV-infected Thai adolescents with low bone mineral density. J Virus Erad. 2018;4(1):6-11. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29568546.
  24. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21118827.
  25. Schall JI, Hediger ML, Zemel BS, et al. Comprehensive safety monitoring of 12-month daily 7000-IU vitamin D3 supplementation in human immunodeficiency virus-infected children and young adults. JPEN J Parenter Enteral Nutr. 2016;40(7):1057-1063. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26160254.
  26. Shen Y, Strehlau R, Shiau S, et al. Bone mass remains higher among children on efavirenz vs lopinavir/ritonavir. Abstract 821. Presented at: Conference on Retroviruses and Opportunistic Infections 2020. Boston, MA. Available at: https://www.croiconference.org/abstract/bone-mass-remains-higher-among-children-on-efavirenz-vs-lopinavir-ritonavir/.
  27. Starup-Linde J, Rosendahl SB, Storgaard M, et al. Management of osteoporosis in patients living with HIV–—a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2020;83(1):1-8. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31809356.
  28. Sudjaritruk T, Bunupuradah T, Aurpibul L, et al. Adverse bone health and abnormal bone turnover among perinatally HIV-infected Asian adolescents with virological suppression. HIV Med. 2017;18(4):235-244. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27477214.
  29. Tebas P, Kumar P, Hicks C, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015;29(18):2459-2464. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26355674.
  30. Torrejon C, Galaz MI, Vizueta E, et al. Evaluation of bone mineral density in children with vertical infection by HIV. Rev Chilena Infectol. 2018;35(6):634-641. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31095183.
  31. Van Welzen BJ, Thielen MAJ, Mudrikova T, et al. Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss? AIDS. 2019. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31021851.
  32. Zemel BS, Kalkwarf HJ, Gilsanz V, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. J Clin Endocrinol Metab. 2011;96(10):3160-3169. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21917867.

 

Management of Medication Toxicity or Intolerance

Osteopenia and Osteoporosis

Table 15j. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis
Table 15j. Antiretroviral Therapy-Associated Adverse Effects and Management Recommendations—Osteopenia and Osteoporosis
   
   
   
   

 

Download Guidelines